Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review. Adv Ther. 2025 Mar; 42(3):1360-1392.
PMID: 39907897
Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry.
Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry. Inflamm Bowel Dis. 2025 Jan 08.
PMID: 39779464
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease.
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025 01 06; 31(1):63-71.
PMID: 38916136
Editorial.
Editorial. Curr Opin Gastroenterol. 2025 Jan 01; 41(1):1-2.
PMID: 39633584
Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn's Disease.
Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn's Disease. Clin Gastroenterol Hepatol. 2024 Oct 24.
PMID: 39461462
A Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease.
A Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease. Crohns Colitis 360. 2024 Jul; 6(3):otae045.
PMID: 39347443
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease.
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 Jun 25.
PMID: 38916136
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center.
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
PMID: 38087126
Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center.
Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
PMID: 38065372
A plain language summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body.
A plain language summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body. Immunotherapy. 2023 12; 15(18):1501-1509.
PMID: 38031712